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Background: On December 8th, 2015, World Health Organization published a priority list of eight pathogens
expected to cause severe outbreaks in the near future. To better understand global research trends and
characteristics of publications on these emerging pathogens, we carried out this bibliometric study hoping to
contribute to global awareness and preparedness toward this topic.
Method: Scopus database was searched for the following pathogens/infectious diseases: Ebola, Marburg, Lassa, Rift
valley, Crimean-Congo, Nipah, Middle Eastern Respiratory Syndrome (MERS), and Severe Respiratory Acute
Syndrome (SARS). Retrieved articles were analyzed to obtain standard bibliometric indicators.
Results: A total of 8619 journal articles were retrieved. Authors from 154 different countries contributed to
publishing these articles. Two peaks of publications, an early one for SARS and a late one for Ebola, were observed.
Retrieved articles received a total of 221,606 citations with a mean ± standard deviation of 25.7 ± 65.4 citations per
article and an h-index of 173. International collaboration was as high as 86.9%. The Centers for Disease Control and
Prevention had the highest share (344; 5.0%) followed by the University of Hong Kong with 305 (4.5%). The top
leading journal was Journal of Virology with 572 (6.6%) articles while Feldmann, Heinz R. was the most productive
researcher with 197 (2.3%) articles. China ranked first on SARS, Turkey ranked first on Crimean-Congo fever, while
the United States of America ranked first on the remaining six diseases. Of retrieved articles, 472 (5.5%) were on
vaccine – related research with Ebola vaccine being most studied.
Conclusion: Number of publications on studied pathogens showed sudden dramatic rise in the past two decades
representing severe global outbreaks. Contribution of a large number of different countries and the relatively high
h-index are indicative of how international collaboration can create common health agenda among distant
different countries.
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Background
On December 8th, 2015, World Health Organization
(WHO) led a meeting of experts and health consultants
in Geneva to discuss and publish a priority list of patho-
gens likely to cause serious outbreaks in the near future
bearing in mind that the suggested pathogens had
limited or no available effective therapies or preventive
measures [1]. The meeting came up with a list of top
eight emerging serious pathogens that are of great harm-
ful health consequences. According to WHO, the list is
not an ultimate one and is supposed to be reviewed
annually to include any new emerging pathogens. The
WHO list aims to lay the basis and background for na-
tional and international health planning to combat and
control any potential outbreaks of these pathogens. Fur-
thermore, the WHO wanted countries, researchers,
clinicians, and policy makers to talk about these patho-
gens and corresponding infectious diseases as part of
global awareness and preventive policies which mightCorrespondence: waleedsweileh@yahoo.comDepartment of Physiology and Pharmacology/Toxicology, College of
Medicine and Health Sciences, An-Najah National University, Nablus,
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include developing new and inexpensive diagnostics,
therapies, vaccines, and behavioral health measures.
According to WHO, the list of pathogens, which re-
quired urgent attention for research and development
pertaining to preparedness, included “Crimean Congo
haemorrhagic fever, Ebola virus, Marburg, Lassa fever,
Middle East respiratory syndrome (MERS) and Severe
acute respiratory syndrome (SARS) coronavirus diseases,
Nipah, and Rift Valley fever” [1]. These infectious dis-
eases are caused by viruses and some of them, such as
Crimean-Congo and Ebola, are associated with high fa-
tality rate [2–8]. Marburg virus is transmitted to people
from fruit bats and spreads among humans through
human-to-human transmission [9–13] while Lassa fever
is transmitted to humans through food contaminated
with rodent feces or urine [14, 15]. Middle East respira-
tory syndrome is caused by a coronavirus that was first
identified in Saudi Arabia in 2012 [16–18] while SARS,
another coronavirus respiratory disease, was recognized
on February 2003 [19, 20]. Nipah virus, identified in
1998, is emerging zoonosis that affects both animals and
humans [13, 21–24]. Rift Valley fever is a viral zoonosis
that was first identified among sheep on a farm in the
Rift Valley of Kenya [25–29]. The WHO committee
listed another three pathogens/infectious diseases and
considered them as serious and require an action as
soon as possible. These three serious diseases include
Chikungunya, severe fever with thrombocytopenia syn-
drome, and Zika.
Literature review using Pubmed, Google Scholar and
Scopus showed that bibliometric studies on SARS or
Ebola or Nipah virus have been carried out, but as a sin-
gle disease and not as a group of diseases with potential
future severe epidemics [25–29]. The collective analysis
of literature on top eight pathogens will give a more
comprehensive view on these infectious diseases and will
help identify which one needs to be given top priority
for funding and research.
It has been reported that mapping literature with cer-
tain statistical methods could help in detection of emer-
ging infectious disease outbreaks particularly in the
presence of internet with thousands of reports being eas-
ily communicated among public health specialists and
healthcare providers [30, 31]. Based on all of the above,
we carried out this bibliometric study to analyze litera-
ture on top eight emerging pathogens suggested by
WHO. Specifically, information regarding number of
publications over time, contribution of various countries,
international collaboration, active authors and institu-
tions, journals that are actively publishing articles, cita-
tions analysis, geographical distribution of publications,
visualization of inter-country collaboration, and top cited
articles will be presented. This kind of analysis will be of
value to virologists, pharmacist, medicinal chemist, and
clinicians who are interested in infectious viral diseases
and in developing effective preventive and curative
pharmaceutical products. Young researchers need to dir-
ect their research efforts toward emerging diseases
because they are considered top priority and a bulk of fi-
nancial support will be invested in these diseases.
Healthcare workers in the field of travel medicine need
to be aware of the map of infectious diseases that
quickly cross borders from one country to another lead-
ing to spread of diseases with potential negative impact
on public health and tourism industry.
Methods
For this study, Scopus search engine was chosen to re-
trieve required literature. Scopus was used because of its
advantages over other databases such as Web of Science
(WoS), Google scholar or Pubmed [32]. According to
Falagas et al. study, no database is perfect and each has
certain merits over the other. For example, PubMed and
Google Scholar are free to use in contrast to Scopus and
WoS. PubMed lacks citation analysis in contrast to other
databases. Scopus offers about 20% more coverage than
Web of Science and 100% of Medline database is cov-
ered by Scopus. Google Scholar is the largest in terms of
coverage but results obtained by Google Scholar have in-
consistent accuracy. Although Scopus covers a wider
journal range, it is currently limited to articles published
after 1995 when compared with WoS [32]. In the
current study, we preferred the use of Scopus because of
its wider coverage since we are interested in global re-
search activity in the eight emerging pathogens. Many of
the journals published from developing countries, where
these infectious diseases were found, are indexed in Sco-
pus. This is reflected in the number of journals covered
by Scopus versus those covered by WoS [32].
In the current study, keywords used were the names of
diseases that appeared in the WHO top eight list. To
avoid errors, the names of diseases were followed by
conditional keywords such as “virus OR viral OR fever
OR hemorrhagic OR haemorrhagic OR corona* OR cor-
onavirus OR infection OR infectious). Fig. 1 illustrates
the steps followed along with keywords and search query
used in Scopus to retrieve required data.
The data obtained were refined using the side func-
tions in Scopus. Such functions include: 1) time limita-
tion which was set for this study from 1996 to 2015, 2)
source type of data which was set in this study to be
journal articles while books and book chapters were
excluded, and finally 3) type of documents and for the
purpose of this study all types of documents were in-
cluded except errata (correction).
Analysis of data was carried out using the “analyze”
function in Scopus menu bar. Analysis included annual
number of published documents, productivity of each
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country, author, preferred journals for publishing re-
search on top eight emerging pathogens, geographical
distribution, network visualization, and institution/
organization. Scopus allows for citation analysis such as
total number of citations, Hirsch index (h-index), and
top cited articles. The h-index is a parameter used to
measure productivity and scientific impact of an author,
institution, or country, or even a subject area [33]. Sco-
pus can also give analysis about active journals in pub-
lishing articles on studied diseases. Active journals were
presented along with Impact Factor (IF) which was ob-
tained from the Journal Citation Report published by
Thomson Reuters.
An important feature in Scopus is that it allows exclu-
sion or limitation which allow researchers to identify
articles published by a single author or a single country.
Based on this, we divided articles into two types: (1) sin-
gle country publications (SCP) in which all authors have
the same country affiliation and such publications repre-
sent an intra-country collaboration, and (2) multiple
country publications (MCP) in which authors have dif-
ferent country affiliation and such publications represent
inter-country collaboration.
In bibliometric studies, not all data can be
presented. In most bibliometric studies, active or
most productive countries, authors, institutions/orga-
nizations, and journals are usually presented. In this
study, with large number of retrieved documents, only
countries, authors, institutions, and journals with a
minimum productivity of 100 documents were pre-
sented and ranked. The cutoff point of 100 publica-
tions have been previously used in other bibliometric
studies [34]. For analysis pertaining to each infectious
disease, only the top 10 productive countries were
presented.
An important preventive aspect of most serious infec-
tious diseases is the development of vaccines for preven-
tion of spread. In this study, publications pertaining to
vaccine development against any one of the top eight
emerging pathogens were sought and presented. The
search query used to search for vaccine development
was the same search query used to retrieve publications
on the top eight pathogens plus the keyword “vaccin*”
with an asterisk to retrieve words such as vaccine or vac-
cination. The complete search query for vaccine data
was presented in Fig. 1.
Search query:
(TITLE("Crimean-Congo" OR Ebola OR "Middle East Respiratory Syndrome" OR "Severe acute respiratory syndrome" OR Lassa OR Nipah 
OR "Rift valley" OR Marburg OR MERS OR MERS-CoV OR SARS OR Ebolavirus OR Crimean) AND TITLE-ABS(virus OR viral OR 
fever OR hemorrhagic OR haemorrhagic OR corona* OR coronavirus OR infection OR infectious)) AND PUBYEAR > 1995 AND 
PUBYEAR < 2016
N = 9051
Limit to Journal articles:
N = 8703
Exclude errata documents:
(TITLE("Crimean-Congo" OR Ebola OR "Middle East Respiratory Syndrome" OR "Severe acute respiratory syndrome" OR Lassa OR Nipah 
OR "Rift valley" OR Marburg OR MERS OR MERS-CoV OR SARS OR Ebolavirus OR Crimean) AND TITLE-ABS(virus OR viral OR 
fever OR hemorrhagic OR haemorrhagic OR corona* OR coronavirus OR infection OR infectious)) AND PUBYEAR > 1995 AND 
PUBYEAR < 2016 AND (LIMIT-TO(SRCTYPE,"j" ) ) AND ( EXCLUDE(DOCTYPE,"er" ) )
N = 8619
Search query for vaccine related documents:
( TITLE ( "Crimean-Congo" OR ebola OR "Middle East Respiratory Syndrome" OR "Severe acute respiratory 
syndrome" OR lassa OR nipah OR "Rift valley" OR marburg OR mers OR mers-
cov OR sars OR ebolavirus OR crimean ) AND TITLE-
ABS ( virus OR viral OR fever OR hemorrhagic OR haemorrhagic OR corona* OR coronavirus OR infection OR infectious ) AND
TITLE ( vaccin* ) ) AND PUBYEAR > 1995 AND PUBYEAR < 2016 AND ( LIMIT-
TO ( SRCTYPE , "j" ) ) AND ( EXCLUDE ( DOCTYPE , "er" ) )
N = 472
Fig. 1 Strategy and search query used to retrieve required data in Scopus
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Statistical Package for Social Sciences (SPSS - 21) was
used to create graphs pertaining to growth of publica-
tions for each disease. Mean ± standard deviation (SD)
and median (Q1 – Q3) were used for descriptive statis-
tics. Finally, bibliometric studies do not involve human
or animal subjects and therefore, no ethical approval by
Institutional Review Board was required.
Results
A total of 8619 journal articles were retrieved. The high-
est number of published articles was recorded in 2015
while the lowest number of published articles was re-
corded in 1996. The growth of publications showed a
rising trend in 2003 and 2004 and then in 2014 and
2015. Figure 2 shows the annual growth of publications
during the study period.
A total of 28 different languages were encountered in
retrieved articles. English (n = 7,661; 88.9%) was the
most common followed by Chinese (n = 387; 4.5%),
French (206; 2.4%), and Russian (n = 131; 1.5%). The
majority of retrieved articles were research articles
(n = 6,587; 76.4%). Other types of retrieved docu-
ments are shown in Table 1.
The majority of articles (n = 5,406; 62.7%) were pub-
lished in peer reviewed journals in the subject area of
“Medicine” while 3075 (35.7%) were published in peer
reviewed journals in the subject area of “Immunology
and Microbiology”. The subject areas with a minimum
of 100 articles are shown in Table 2. Since some journals
fit into more than one subject area, the total percentages
in Table 2 exceeded 100%.
Citation analysis
Retrieved documents received a total of 221,606
citations. The mean ± SD was 25.7 ± 65.4 citations per
documents while the median (Q1 – Q3) was 9 (2–27).
The h-index was 173. A total of 7291 (84.6%) articles
were cited at least once while 1328 (15.4%) articles were
not cited at all. A total of 408 (4.7%) publications
received a minimum of 100 citations per article.
Fig. 2 Annual growth of publications over the study period (1996–2015)
Table 1 Types of retrieved documents





Conference Paper 192 2.2
Editorial 141 1.6
Short Survey 107 1.2
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The article that received the highest number of cita-
tions was “A novel coronavirus associated with severe
acute respiratory syndrome” [35] published in New
England Journal of Medicine (NEJM) in 2003. It received
a total of 1979 citations. Table 3 shows the top 20 cited
articles. Content analysis of top cited articles showed
that 18 articles were about SARS, one about Nipah virus
and one about Ebola virus. Five of top cited articles were
published in NEJM, three in Lancet, six in Science, and
three in Nature.
Country analysis
Researchers from 154 different countries participated in
publishing retrieved articles. Table 4 shows a list of
countries with a minimum contribution of 100 articles.
The list included 23 different countries in North
America, Middle East, Europe, Asia, Australia, and
Africa. The total number of articles produced by the list
of active countries was 6892 (80.0%). The United States
of America (USA) ranked first in productivity with a
Table 2 Subject areas of retrieved documents
Subject area Frequency % N = 8619 a
Medicine 5406 62.7
Immunology and Microbiology 3075 35.7
Biochemistry, Genetics and Molecular Biology 1681 19.5
Pharmacology, Toxicology and Pharmaceutics 533 6.2
Agricultural and Biological Sciences 407 4.7
Veterinary 283 3.3
Multidisciplinary 234 2.7
Social Sciences 179 2.1
Chemistry 170 2.0
Environmental Science 133 1.5
Nursing 123 1.4
aDue to overlap among subject areas, the total percentages exceeded 100%
Table 3 Top cited 20 articles on top eight emerging pathogens/infectious diseases
Article Year Journal Number of citations
A novel coronavirus associated with severe acute respiratory syndrome [35] 2003 New England Journal of Medicine 1979
Identification of a novel coronavirus in patients with severe acute respiratory
syndrome [93]
2003 New England Journal of Medicine 1810
Coronavirus as a possible cause of severe acute respiratory syndrome [94] 2003 Lancet 1535
Characterization of a novel coronavirus associated with severe acute respiratory
syndrome [95]
2003 Science 1479
The genome sequence of the SARS-associated coronavirus [96] 2003 Science 1295
A major outbreak of severe acute respiratory syndrome in Hong Kong [97] 2003 New England Journal of Medicine 1135
Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus [98]
2003 Nature 943
Clinical progression and viral load in a community outbreak of coronavirus-
associated SARS pneumonia: A prospective study [99]
2003 Lancet 916
Isolation and characterization of viruses related to the SARS coronavirus from
animals in Southern China [99]
2003 Science 895
Identification of severe acute respiratory syndrome in Canada [100] 2003 New England Journal of Medicine 827
Bats are natural reservoirs of SARS-like coronaviruses [101] 2005 Science 720
A cluster of cases of severe acute respiratory syndrome in Hong Kong [102] 2003 New England Journal of Medicine 677
Unique and conserved features of genome and proteome of SARS-coronavirus,
an early split-off from the coronavirus group 2 lineage [103]
2003 Journal of Molecular Biology 638
Fruit bats as reservoirs of Ebola virus [104] 2005 Nature 606
Nipah virus: A recently emergent deadly paramyxovirus [105] 2000 Science 605
Clinical Features and Short-term Outcomes of 144 Patients with SARS in the
Greater Toronto Area [106]
2003 Journal of the American Medical
Association
603
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe
bats [107]
2005 PNASa 568
Koch’s postulates fulfilled for SARS virus [108] 2003 Nature 554
Transmission dynamics and control of severe acute respiratory syndrome [109] 2003 Science 535
Epidemiological determinants of spread of causal agent of severe acute
respiratory syndrome in Hong Kong [110]
2003 Lancet 515
aPNAS Proceedings of the National Academy of Sciences
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total of 2852 (33.1%) followed by China (n = 1,057; 12.3%),
Hong Kong (n = 548; 6.4%), and Germany (n = 608; 7.1%).
Geographical distribution of worldwide publications on
the top eight emerging pathogens was mapped using
ArcGIS 10.1 with darker colors indicative of higher
productivity (Fig. 3).
International collaboration ranged from 12.1 to 86.9%.
Turkey had the lowest percentage (12.1%) of articles
with international authors while Switzerland had the
highest percentage (86.9%) of articles with international
authors. Only two countries (Turkey and Iran) had less
than 20% international collaboration. There was a sig-
nificant correlation (Pearson correlation r = 0.52; p =
0.01) between percentage of international collaboration
and number of citation per article but not with h-index.
Visualization of international collaboration was created
using VOSviewer technique. In the network visualization
map, the strength of collaboration between countries is
expressed by the thickness of the line between any two
countries. Figure 4 shows inter-country collaboration
between various developed and developing countries.
The thickness of the connecting lines represents the
extent of collaboration between any two countries.
Institutions/organizations
Sixteen intuitions/organizations made a contribution
of a minimum of 100 publications (Table 5). The total
number of documents published by these active insti-
tutions was 3083 (35.8%). Eight active intuitions are
in northern America (USA and Canada), three are in
Hong Kong/China, two in Germany, one in France,
one in Japan, and one is an international organization
(WHO). The Centers for Disease Control and Preven-
tion (CDC) had the highest productivity of 344 (5.5%)
articles followed by the University of Hong Kong with
305 (4.5%) documents. World Health Organization
ranked 12th with 135 (1.6%) documents. However,
publications by WHO had the highest citations per
article (70.3) followed by those published by Univer-
sity of Hong Kong (60.4) and CDC (60.2). The CDC
Table 4 List of countries with a minimum contribution of 100 documents
Country Frequencya % N = 8619 SCP % MCP % TC C/A h-index
USA 2852 33.1 1499 52.6 1353 47.4 111552 39.1 145
China 1057 12.3 604 57.1 453 42.9 23153 21.9 67
Germany 608 7.1 203 33.4 405 66.6 28217 46.4 77
Hong Kong 548 6.4 326 59.5 222 40.5 26917 49.1 71
Canada 527 6.1 202 38.3 325 61.7 21809 41.4 75
France 521 6.0 170 32.6 351 67.4 18658 35.8 68
UK 470 5.5 132 28.1 338 71.9 14704 31.3 60
Japan 324 3.8 121 37.3 203 62.7 8309 25.6 48
Turkey 306 3.6 269 87.9 37 12.1 4375 14.3 30
Taiwan 285 3.3 228 80.0 57 20.0 7161 25.1 39
Singapore 255 3.0 142 55.7 113 44.3 9270 36.4 43
Netherlands 209 2.4 63 30.1 146 69.9 12989 62.1 50
Australia 195 2.3 43 22.1 152 77.9 6262 32.1 43
South Africa 160 1.9 47 29.4 113 70.6 6219 38.9 41
Switzerland 160 1.9 21 13.1 139 86.9 8659 54.1 44
Spain 150 1.7 61 40.7 89 59.3 3883 25.9 33
Saudi Arabia 142 1.6 51 35.9 91 64.1 4733 33.3 38
Italy 140 1.6 54 38.6 86 61.4 2930 20.9 29
India 123 1.4 74 60.2 49 39.8 1207 9.8 18
Belgium 109 1.3 18 16.5 91 83.5 4054 37.2 34
Sweden 104 1.2 33 31.7 71 68.3 2498 24.0 31
Iran 102 1.2 84 82.4 18 17.6 1264 12.4 19
Malaysia 100 1.2 58 58.0 42 42.0 4395 44.0 30
TC total citations, C/A citation per article, h-index Hirsch index, USA United States of America, UK United Kingdom, SCP single country publications, MCP multiple
country publications
aWhen productivity of each country was calculated alone the total number exceeds the number of retrieved articles. However, when productivity of all countries
was dealt with collectively, the total number will be lesser than that presented in the table. The collaboration between countries created some percentage of
overlap and therefore certain number of similar countries were counted twice for collaborating countries
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had the highest (87) h-index followed by U.S. Army
Medical Research Institute of Infectious Diseases (75)
and The University of Hong Kong (63).
Journals and authors
Five journals made a contribution of at least 100 articles
to studied diseases. Top leading journal was Journal of
Virology with 572 (6.6%) articles. The journal is pub-
lished by the American Society of Microbiology and has
an IF of 4.6. The second ranking journal was Emerging
Infectious Diseases with 295 (3.4%) publications; pub-
lished by the CDC and has and IF of 6.99. The third
ranking journal was Journal of Infectious Diseases with
244 (2.8%) articles; published on behalf of Infectious
Diseases Society of America and has an IF of 6.3. The
fourth ranking journal was Virology journal with 194
(2.3%) articles; published by Elsevier and has an impact
factor of 3.2. The fifth ranking journal was Plos One with
146 (1.7%) articles; published by Public Library of
Science, and has an IF of 3.1.
Feldmann, Heinz R. at the National Institutes of
Health, Bethesda, Laboratory of Virology, was the most
productive researcher with 197 (2.3%) articles. Rollin,
Pierre Etienne at CDC, Atlanta, USA ranked second
with 123 (1.4%) articles. Ksiazek, Thomas G. at Galves-
ton National Laboratory, Galveston, USA ranked third
with 118 (1.4%) articles. Nichol, Stuart T., at the
National Center for Emerging and Zoonotic Infectious
Diseases, Atlanta, USA, ranked fourth with 112 (1.3%)
articles. Geisbert, Thomas Thomas, at UT Medical
Branch at Galveston, Department of Microbiology and
Immunology, Galveston, USA ranked fifth with 103
(1.2%) articles. Figure 5 is a visualization map of author
collaboration. The map had 6 clusters of names of au-
thors. Each cluster represents a research group working
on particular pathogen(s).
Publication activity on each disease
Table 6 shows the number of retrieved articles for
each type of disease. Due to the presence of articles
that might have discussed more than one pathogen/
infectious disease at the same time, the total percent-
ages exceeded 100%. Publications on SARS (3379;
39.2%) ranked first in quantity followed by those on
Ebola (2355; 27.3%) and Crimean-Congo (766; 8.9%).
Geographical distribution of research publications on
SARS, Ebola, Crimean – Congo, and MERS were
mapped and presented in Figs. 6, 7, 8 and 9. The an-
nual growth of publications showed that publications
on SARS exhibited a sharp peak in 2003, publications
on Ebola exhibited a sharp peak in 2014, and publica-
tions on MERS exhibited a clear rise starting from
2012 (Fig. 10a and b).
Country analysis of publications on each disease is
shown in Table 7. The USA ranked first in productivity
in research pertaining to Mraburg, Ebola, Rift valley
Fig. 3 Geographical distribution of publications on the eight emerging pathogens. The map was created using ArcGIS 10.1 program. Regions
with no colors in the map have no available data
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Table 5 List of institutions/organizations with a minimum contribution of 100 documents
Institution/Organization Frequency % N = 8619 TC C/A h-index Affiliation
Centers for Disease Control and Prevention (CDC) 422 4.9 25410 60.2 87 USA
The University of Hong Kong 305 3.5 18425 60.4 63 Hong Kong
U.S. Army Medical Research Institute of Infectious Diseases 297 3.4 17027 57.3 75 USA
National Institutes of Health, Bethesda 209 2.4 7072 33.8 44 USA
UT Medical Branch at Galveston 208 2.4 6937 33.4 44 USA
National Institute of Allergy and Infectious Diseases 200 2.3 10371 51.9 56 USA
Universitat Marburg 182 2.1 10159 55.8 52 Germany
Institut Pasteur, Paris 175 2.0 8639 49.4 44 France
University of Manitoba 165 1.9 7289 44.2 51 Canada
National Microbiology Laboratory 163 1.9 7250 44.5 48 Canada
Prince of Wales Hospital Hong Kong 141 1.6 6600 46.8 40 Hong Kong
Organisation Mondiale de la Sante 135 1.6 9496 70.3 44 WHO
National Institute of Infectious Diseases 125 1.5 2356 18.8 28 Japan
Chinese University of Hong Kong 114 1.3 4601 40.4 33 Hong Kong
Bernhard Nocht Institut fur Tropenmedizin Hamburg 108 1.3 7241 67.0 36 Germany
University of Toronto 100 1.2 5071 50.7 32 Canada
TC total citations, C/A citation per article, h-index Hirsch index, USA United States of America, WHO World Health Organization
Fig. 4 Network visualization of inter-country collaborations among countries with minimum of 20 publications on emerging pathogens. Links
represent the strength of collaboration
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fever, Nipah, MERS, and Lassa. However, China ranked
first in SARS while Turkey ranked first in Crimean-
Congo fever. For SARS virus, half of the top 10 list were
Asian countries while for Nipah virus, four Asian
countries appeared in the top 10 list; Malaysia,
Bangladesh, Japan, and Singapore. The USA, the UK,
and Germany appeared in the top 10 productive list for
all diseases. China and/or Hong Kong were in the top 10
productive list for Ebola, MERS, and SARS. Analysis of
h-index of publications pertaining to each disease
showed that publications on Ebola (120) had the highest
h-index followed by SARS (115), Nipah (63) and rift
valley fever (61).
Publications on vaccine development
Four hundred seventy-two publications were related
to vaccine development. Research activity on vaccine
development showed similar trend to overall research
activity on the top eight emerging disease (Fig. 11).
As expected Vaccine journal (68, 14.4%) ranked first
in productivity followed by Journal of Virology (40,
8.5%). The USA was the most productive country in
this field with 254 (53.8%) followed distantly by China
(70; 14.8%) and Canada (54; 11.4%). Professor
Feldmann H. (36; 7.6%) was the most prolific author
in this field. Top 20 cited articles on vaccines against
studied pathogens/infectious diseases are shown in
Table 8. Development of a vaccine against Ebola,
SARS, Nipah, or Lassa was the main focus of vaccine
– related studies. Ten articles in the top 20 list were
about Ebola, five were about SARS, two were about
Marburg, one was about Nipah, one about Lassa
fever, and one article was about both Ebola and
Marburg viruses.
Fig. 5 Network visualization map of author collaboration. Cluster of authors having similar cluster color most probably represents a closely related
research group
Table 6 Number of publications on each disease
Rank Disease Frequency % h-index
1st SARS 3379 39.2 115
2nd Ebola 2355 27.3 120
3rd Crimean – Congo 766 8.9 54
4th Rift valley fever 678 7.9 61
5th MERS 613 7.1 51
6th Nipah 382 4.4 63
7th Marburg 354 4.1 55
8th Lassa 285 3.3 47
SARS Severe acute respiratory syndrome, MERS Middle East respiratory
syndrome, h-index Hirsch index
Due to overlap, total percentage exceeded 100%














Fig. 7 Geographical distribution of publications on Ebola. The map was created using ArcGIS 10.1 program. Regions with no colors in the map
have no available data







Fig. 8 Geographical distribution of publications on Ebola. The map was created using ArcGIS 10.1 program. Regions with no colors in the map







Fig. 9 Geographical distribution of publications on MERS. The map was created using ArcGIS 10.1 program. Regions with no colors in the map
have no available data
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Fig. 10 a Growth of publication on Ebola and SARS (1996–2015). b Growth of publications on “Crimean – Congo, Marburg, Lassa fever, Middle
East respiratory syndrome (MERS), Nipah, and Rift Valley fever” (1996–2015)
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Discussion
This study was carried out to assess worldwide re-
search activity on emerging pathogens expected to
cause serious fatal outbreaks in the near future. Sev-
eral bibliometric studies were carried out and pub-
lished on infectious diseases in general or on a
specific disease such as Ebola [36], SARS [37, 38],
and Nipah [39, 40]. However, no bibliometric study
was carried out on research activity on a group of vi-
ruses suspected of potential outbreaks in the near
future. These emerging pathogens need to be looked
at as one unit since most of them have similar patho-
genic and epidemiologic characteristics.
Our study showed that research activity on emerging
pathogens showed an uprising peak in 2003 due to the
outbreak of SARS at that time, particularly in Asian
countries. Another uprising peak of publications was
seen in 2014 due to outbreak of Ebola virus and to a
lesser extent the outbreak of MERS-CoV. Between the
two peaks of SARS and Ebola, there was a high plateau
Table 7 Top 10 productive countries for each pathogen/infectious disease
SARS Frequency % N = 3379 Crimean-Congo Frequency % N = 766 Marburg Frequency % N = 354
China 811 24.0 Turkey 288 37.6 USA 154 43.5
USA 786 23.3 Iran 91 11.9 Germany 65 18.4
Hong Kong 499 14.8 USA 91 11.9 Canada 29 8.2
Taiwan 276 8.2 UK 45 5.9 Japan 23 6.5
Canada 240 7.1 Germany 41 5.4 France 20 5.6
Singapore 211 6.2 Greece 41 5.4 UK 18 5.1
Germany 167 4.9 France 36 4.7 Belgium 13 3.7
UK 131 3.9 Sweden 35 4.6 Switzerland 13 3.7
Japan 127 3.8 Russian Fed. 27 3.5 South Africa 12 3.4
Netherlands 79 2.3 Bulgaria 24 3.1 Congo 11 3.1
Ebola Frequency % N = 2355 Rift valley fever Frequency % N = 678 MERS Frequency % N = 613
USA 1147 48.7 USA 263 38.8 USA 201 32.8
Canada 192 8.2 France 124 18.3 Saudi Arabia 96 15.7
France 192 8.2 South Africa 75 11.1 China 82 13.4
Germany 186 7.9 Kenya 68 10.0 UK 55 9.0
UK 160 6.8 Senegal 46 6.8 Germany 54 8.8
China 122 5.2 UK 41 6.0 Hong Kong 45 7.3
Japan 113 4.8 Saudi Arabia 31 4.6 Netherlands 44 7.2
Switzerland 66 2.8 Egypt 28 4.1 South Korea 37 6.0
Nigeria 58 2.5 Germany 28 4.1 France 27 4.4
India 56 2.4 Netherlands 27 4.0 Japan 23 3.8
Nipah Frequency % N = 382 Lassa Frequency % N = 285
USA 186 48.7 USA 123 43.2
Malaysia 88 23.0 Germany 74 26.0
Australia 66 17.3 France 34 11.9
Bangladesh 29 7.6 Nigeria 32 11.2
France 25 6.5 Sierra Leone 19 6.7
Canada 23 6.0 Guinea 17 6.0
Japan 19 5.0 Canada 15 5.3
Germany 17 4.5 UK 12 4.2
Singapore 16 4.2 Netherlands 10 3.5
UK 15 3.9 Belgium 9 3.2
Japan 9 3.2
SARS Severe acute respiratory syndrome, MERS Middle East respiratory
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of research activity that is most probably due to the rise
in the number of publications about the remaining five
diseases.
International collaboration in research on emerging
diseases was high possibly due to spread of these viral
infectious outbreaks across borders. Furthermore, the
relatively high h-index of 173 indicates that research on
these diseases is receiving a high number of citations
suggestive of importance and large number of readers. A
study concluded that the h-index can be used to esti-
mate the potential impact of a pathogen and to rank in-
dividual pathogens or types of pathogens [41]. In our
study, Ebola and SARS had the highest h-indices which
necessitate prioritizing these two pathogens in planning
for the future preventive policies. The finding that
Professor Feldmann, R. was the most prolific researcher
was confirmed by other bibliometric studies [34].
Infectious diseases like acquired immune deficiency
syndrome (AIDS), malaria, and tuberculosis are major
infectious diseases affecting millions of people and
draining billions of US dollars of research funds [42, 43].
Research activity on malaria, tuberculosis, and AIDS
have made some success in controlling the spread of
such diseases and in developing potent and effective
therapies. For example, the discovery of the effective
drug artemisinin has greatly changed the therapeutic ap-
proach of malaria and enhanced control and eradication
of malaria [44–46]. Actually, the Chinese scientist Tu
Youyou, who discovered the drug artemisinin, was
awarded Nobel Prize in Medicine in 2015 [47, 48]. In
case of the top eight emerging pathogens which are ex-
pected to cause serious outbreaks in the near future, no
effective therapy is available so far and no preventive
measures are being developed to face a sudden world-
wide outbreak of these infectious diseases. Calls for
strengthening preparedness for Crimean-Congo [49] and
MERS-coronavirus [50–52] have been published. The
WHO stated that research remains the cornerstone for
reversing trends of serious outbreaks of certain viral dis-
eases and that research will improve methods for
surveillance, prevention, and control. Unfortunately, the
increased funding for AIDS created a shortage of fund-
ing for other infectious diseases [53]. A study that
compared research output and citations among three in-
fectious diseases indicated that funding has a positive
influence on research output and citations for a particu-
lar disease [54].
In most bibliometric studies, the USA, the UK,
Germany, and other European countries appeared in the
most active list of publications. However, in this study,
additional countries in Asia and Africa, and Middle east
did appear in the top active list for each disease empha-
sizing the global threat of such infectious diseases. A
bibliometric analysis on infectious diseases reported that
USA ranked as top productive country but China is in-
creasing its place among the top five countries [55].
Fig. 11 Growth of publications on vaccine research on emerging pathogens (1996–2015)
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Actually, many countries start to focus their research ef-
forts on infectious diseases as a national health burden
[56]. The participation of Asian, African, and Middle
eastern countries in research activity pertaining to top
eight emerging infectious diseases was clear and promin-
ent. Outbreaks of emerging viral infectious diseases have
been commonly reported from many countries in Africa,
Asia, and Africa [52, 57–62]. For example, MERS-CoV
and Crimean-Congo fever have been reported in more
than 20 countries, mostly in Asia, Africa, and Middle
East [63–77]. The outbreaks of SARS in Hong Kong and
China had a great economic and public health impact
[78–80]. Many of these infectious diseases were initially
reported in Africa, such as Ebola, Lassa fever, and Rift
valley fever [81–86]. The Marburg virus was initially
reported in Germany and spread to other neighboring
countries and that is why China and Hong Kong did not
show in the top productive countries on Marburg
disease.
Our study has few limitations that need to be stated.
Scopus is a large and comprehensive database but not
all journals are indexed in Scopus and therefore, some
articles about the studied diseases published in un--
indexed journals might be missed. Furthermore, the key-
words used might not be 100% accurate although the
validity of the search query was tested by manual review
of 10% of retrieved articles, false positive and false nega-
tive results remain a possibility. The ranking of countries
and institutions based on citations did not take into ac-
count self-citations which affects the validity of results.
Table 8 Top 20 cited articles on vaccine – related publication on studied diseases
Title Year Journal Number of citations
Development of a preventive vaccine for Ebola virus infection in primates [111] 2000 Nature 490
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
[112]
2003 Nature 336
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and
Marburg viruses [113]
2005 Nature Medicine 320
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in
mice [114]
2004 Nature 320
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated
vaccinia virus protectively immunizes mice [115]
2004 PNAS 232
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and
nonhuman primates [116]
1998 Virology 199
Effects of a SARS-associated coronavirus vaccine in monkeys [117] 2003 Lancet 168
Ebola virus: From discovery to vaccine [118] 2003 Nature Reviews Immunology 168
Evaluation in nonhuman primates of vaccines against Ebola virus [119] 2002 Emerging Infectious Diseases 166
Severe acute respiratory syndrome vaccine development: Experiences of vaccination
against avian infectious bronchitis coronavirus [120]
2003 Avian Pathology 152
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola
virus challenge [121]
2007 Journal of Infectious Diseases 149
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glyco-
protein: interim results from the Guinea ring vaccination cluster-randomised trial [122]
2015 The Lancet 137
DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from
lethal challenge [123]
1998 Virology 136
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial [124] 2006 Clinical and Vaccine
Immunology
134
Single-injection vaccine protects nonhuman primates against infection with Marburg
virus and three species of Ebola virus [125]
2009 Journal of Virology 127
Development of a new vaccine for the prevention of Lassa fever [126] 2005 PLoS Medicine 115
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing
antibodies: Implication for developing subunit vaccine [127]
2004 Biochemical and Biophysical
Research Communications
115
Correlates of protective immunity for Ebola vaccines: Implications for regulatory
approval by the animal rule [128]
2009 Nature Reviews Microbiology 105
Nipah Virus: Vaccination and Passive Protection Studies in a Hamster Model [129] 2004 Journal of Virology 105
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of
severe acute respiratory syndrome coronavirus induces protective neutralizing
antibodies primarily targeting the receptor binding region [130]
2005 Journal of Virology 101
PNAS Proceedings of the National Academy of Sciences
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These limitations and others are found in most biblio-
metric studies [71, 87–91]. This study focused only on
the top eight emerging infectious diseases expected to
cause severe outbreaks in the near future. However, the
other three serious infectious diseases which in include
Zaika were not included in the analysis. Finally, we
should always bear in mind that no database is perfect
and even might have some bias by over-representing
journals with English language. Therefore, bibliometric
results should always be considered with caution [92].
Conclusions
The number of publications on diseases expected to
cause severe outbreaks in the near future showed two
clear peaks in the past two decades; one for SARS and
one for Ebola. The clear increase in number of publica-
tion on the studied diseases during relatively short
period of time is an indication of how science and health
information flows rapidly across borders to create simi-
lar concerns among different countries. Bibliometric
methods can be used to prioritize efforts and direct re-
search funds to help control emerging diseases [41]. Al-
though the USA is leading the research on these
diseases, the share of Asian, African, and Middle Eastern
countries was apparent. International collaboration in
research on these diseases was relatively high for most
countries. Search for an effective vaccine was clearly
strong for Ebola and SARS.
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